Golf. The FDA would require a far larger pivotal trial to show clinically significant risk reduction before approving for Alzheimer’s. This would require major funding and make AMRN a more serious take over target by a well funded BP If eventually approved the new indication would have exclusivity for some years
Pt being. A successful BRAVE would drive BP take over interest Kiwi